Latest Period
Q1 2026
Security Snapshot
Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share (ELVN) Institutional Ownership
CUSIP: 29337E102
13F Institutional Holders and Ownership History from Q1 2023 to Q1 2026
Institutions Reporting
168
Shares (Excl. Options)
61,617,761
Price
$39.20
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.001 par value per share
- Symbol
- ELVN on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 61,617,761
- Total 13F value
- $2,415,321,021
- Portfolio coverage rank
- 0.01%
- Share change
- -1,386,656
- Value change
- +$69,950,617
- Number of holders
- 168
- Shares outstanding
- 59,773,132
- SEC-reported price per share
- $43.56
- Insider filing price
- $43.56
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- ELVN - Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share is tracked under CUSIP 29337E102.
- 168 institutions reported positions in Q1 2026.
- 8 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 125 to 168 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $960,824,930 to $2,415,321,021.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 168 institutions filings for Q1 2026.
Security key
29337E102
Latest holder period
Q1 2026
13F holders
168
13D/G owners
8
CIK / CUSIP context first
Open Q1 2026 holders
ELVN full holder history
Enliven Therapeutics, Inc. SEC filings
Enliven Therapeutics, Inc. company facts
Enliven Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 29337E102:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
8
Security
ELVN
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 13% | $140,468,212 | 7,918,163 | ORBIMED ADVISORS LLC | 16 Jun 2025 | |||
| FMR LLC | 13% | $161,103,383 | 7,870,219 | FMR LLC | 30 Sep 2025 | |||
| Polar Capital Holdings Plc | 8.5% | +66% | $229,174,493 | +$114,203,046 | 5,056,807 | +99% | Polar Capital Holdings Plc | 31 Mar 2026 |
| Commodore Capital LP | 7.7% | -22% | $217,578,601 | -$55,381,810 | 4,800,940 | -20% | Commodore Capital LP | 31 Mar 2026 |
| Vestal Point Capital, LP | 5.4% | -16% | $147,290,000 | -$26,285,600 | 3,250,000 | -15% | Vestal Point Capital, LP | 31 Mar 2026 |
| BlackRock, Inc. | 5.1% | $59,005,266 | 2,941,395 | BlackRock, Inc. | 30 Jun 2025 | |||
| Fairmount Funds Management LLC | 3.1% | -53% | $84,097,786 | -$84,104,856 | 1,855,644 | -50% | Fairmount Funds Management LLC | 31 Mar 2026 |
| Venrock Healthcare Capital Partners III, L.P. | 2.8% | -52% | $78,237,321 | -$67,980,000 | 1,726,331 | -46% | Venrock Healthcare Capital Partners III, L.P. | 31 Mar 2026 |
As of 31 Mar 2026, 168 institutional investors reported holding 61,617,761 shares of Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share (ELVN). This represents 103% of the company’s total 59,773,132 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
85%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 13% | 7,959,538 | 0% | 7.1% | $312,013,890 |
| FMR LLC | 11% | 6,829,246 | -3.9% | 0.01% | $267,706,443 |
| Polar Capital Holdings Plc | 8.5% | 5,065,933 | +44% | 0.87% | $198,584,574 |
| BlackRock, Inc. | 6.2% | 3,684,707 | +2% | 0% | $144,440,514 |
| Commodore Capital LP | 5.5% | 3,275,000 | -30% | 7.4% | $128,380,000 |
| Vestal Point Capital, LP | 5.4% | 3,250,000 | -15% | 3.6% | $127,400,000 |
| Bellevue Group AG | 3.9% | 2,320,867 | 2.2% | $90,977,986 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.6% | 2,168,162 | 0% | 0% | $84,991,950 |
| Fairmount Funds Management LLC | 3.1% | 1,855,644 | -50% | 5.3% | $72,741,245 |
| CITADEL ADVISORS LLC | 2.9% | 1,743,915 | +22% | 0.05% | $68,361,468 |
| Venrock Adviser, LLC | 2.9% | 1,726,331 | -46% | 2.5% | $67,672,175 |
| NOVO HOLDINGS A/S | 2.1% | 1,280,000 | -14% | 4.1% | $50,176,000 |
| STATE STREET CORP | 1.8% | 1,091,106 | +3.6% | 0% | $42,771,355 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.8% | 1,066,420 | +1.7% | 0% | $41,813,049 |
| Pictet Asset Management Holding SA | 1.6% | 929,544 | -29% | 0.04% | $36,438,125 |
| BAKER BROS. ADVISORS LP | 1.5% | 905,191 | +234% | 0.2% | $35,483,487 |
| Rock Springs Capital Management LP | 1.4% | 826,500 | +3.5% | 1.9% | $32,398,800 |
| Siren, L.L.C. | 1.2% | 746,226 | 0.81% | $29,252,059 | |
| DIMENSIONAL FUND ADVISORS LP | 1.1% | 681,715 | +71% | 0.01% | $26,714,134 |
| First Turn Management, LLC | 1% | 623,839 | 2.7% | $24,454,489 | |
| Candriam S.C.A. | 0.99% | 594,079 | +31% | 0.12% | $23,287,897 |
| Jones Hill Capital LP | 0.99% | 593,040 | 0% | 5% | $23,247,168 |
| Affinity Asset Advisors, LLC | 0.98% | 586,904 | 1.3% | $23,006,637 | |
| Logos Global Management LP | 0.9% | 540,000 | +59% | 1.1% | $21,168,000 |
| MORGAN STANLEY | 0.87% | 518,572 | +26% | 0% | $20,328,037 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
13
Latest
Q1 2026
Rows shown
1-13 of 13
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 61,617,761 | $2,415,321,021 | +$69,950,617 | $39.20 | 168 |
| 2025 Q4 | 62,391,024 | $960,824,930 | +$20,216,707 | $15.40 | 125 |
| 2025 Q3 | 59,389,507 | $1,215,687,864 | -$296,366 | $20.47 | 132 |
| 2025 Q2 | 59,434,902 | $1,192,251,085 | +$192,194,924 | $20.06 | 123 |
| 2025 Q1 | 49,886,849 | $983,923,667 | +$4,352,699 | $19.68 | 118 |
| 2024 Q4 | 49,624,914 | $1,116,597,658 | +$24,828,957 | $22.50 | 111 |
| 2024 Q3 | 47,688,348 | $1,218,010,157 | -$20,810,259 | $25.54 | 100 |
| 2024 Q2 | 48,318,843 | $1,129,194,355 | +$91,652,714 | $23.37 | 91 |
| 2024 Q1 | 44,456,336 | $780,753,492 | +$95,045,035 | $17.59 | 72 |
| 2023 Q4 | 39,000,634 | $539,791,932 | -$652,659 | $13.84 | 61 |
| 2023 Q3 | 39,076,502 | $533,779,750 | -$2,178,662 | $13.66 | 60 |
| 2023 Q2 | 39,092,843 | $797,915,923 | +$112,876,379 | $20.41 | 61 |
| 2023 Q1 | 33,557,749 | $734,910,999 | +$734,911,000 | $21.90 | 44 |